Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of 89Zr-girentuximab for PET Imaging in Residual or Recurrent Post Ablative Tumors in Patients With Renal Cell Carcinoma.

NCT07077083 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07077083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of 89Zr-girentuximab for PET Imaging in Residual or Recurrent Post Ablative Tumors in Patients With Renal Cell Carcinoma.
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 16, 2026
Completion date
August 1, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ccrcc, clear cell renal cell carcinoma (ccrcc)